— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.
— Total revenue stood at $1.96 million vs. $3.68 million expected.
— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.
— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.
— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
